Key highlights

  • Archer Materials shares traded at $0.190 at 11:04 AM AEDT on 19 November 2026, up 11.77%, while the S&P/ASX 200 was up 0.83% around midday.
  • The company completed a Beta prototype of its Biosensor kit, which it says returns a result in about six minutes from a fingerprick sample.
  • Lithium testing is the initial application, with discussions under way with tier-one clinical partners.

Shares in Archer Materials Limited (ASX:AXE) were trading at $0.190 during the session on 19 November 2026, up 11.77% at 11:04 AM AEDT, while the S&P/ASX 200 was up 0.83% at 8,748.30 around midday. Archer describes itself as a quantum technology company developing computing, sensing and medical diagnostic technologies. On 19 November 2026 it announced the completion of a beta prototype of its Biosensor point-of-care blood-testing kit, which moves the program from internal engineering toward external testing and clinical trials.

An Integrated Testing Kit

The beta prototype brings together the cartridge, chip packaging, sensors, reader and readout electronics into one kit that supports the full workflow, from blood sample application through to a displayed result. The company says the kit is designed to be operated end to end by external users, which will allow it to assess performance, sample handling and usability outside its own engineering team.

Path to External Validation

Archer is in discussions with tier-one clinical partners in Australia and internationally to carry out external validation. One planned element is a comparison of its lithium testing application against established laboratory methods. Blood potassium testing is identified as a later application in the broader diagnostic pipeline, and the beta prototype is also ready for initial Manufacturing design with specialist contract manufacturers.

Sector Context

Point-of-care blood testing aims to move analysis out of central laboratories and into clinics or other settings. Lithium monitoring is a long-established clinical test, and the company has said clinical customer feedback drove its choice of lithium as the first application. Devices of this type must generally demonstrate accuracy in independent studies before they can be commercialised.

Risks Investors Are Watching

The announcement does not include clinical performance data from the beta prototype. External validation results, partner agreements and regulatory approvals are all still to come, and the timing of each depends on those steps. Archer is a technology company with several programs running across quantum computing, sensing and medical diagnostics.

What to Watch Ahead

The next items to track are the start of external testing, any agreements with clinical partners, and progress on initial manufacturing design. Results from the external validation work will show how the device performs in real-world clinical settings.

Session Context

The shares were trading at $0.190 during the session on 19 November 2026, up 11.77% at 11:04 AM AEDT. These are intraday figures rather than a closing price, so the move reflects trade in progress at that time. Over the same period the S&P/ASX 200 was up 0.83% at 8,748.30 around midday. In the previous session on 18 November, the Dow Jones closed down 1.32% and the Nasdaq closed down 0.02%. Trading conditions can change quickly during a session, so later moves may differ from the figures shown here.

About the Company

Archer Materials Limited is an ASX-listed quantum technology company based in Adelaide, South Australia. It describes itself as operating within the semiconductor industry, developing advanced chips relevant to quantum computing, sensing and medical diagnostics. The company says it uses global partnerships to develop these technologies for potential deployment across multiple industries. Chief Executive Dr Simon Ruffell has said the next phase is about building evidence on how the device performs in practical settings and using feedback from manufacturing and clinical partners to guide final development.

Closing Note

Archer shares rose in mid-morning trade on the day the company reported the completed beta prototype. Whether the device moves from engineering milestone to clinical evidence will depend on the external studies that follow.